

# Tanja D De Gruijl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7882080/publications.pdf>

Version: 2024-02-01

245  
papers

11,547  
citations

31976

53  
h-index

39675

94  
g-index

248  
all docs

248  
docs citations

248  
times ranked

15917  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional delivery of viral miRNAs via exosomes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6328-6333.	7.1	1,437
2	Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncology, The, 2012, 13, 509-517.	10.7	390
3	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nature Communications, 2018, 9, 4664.	12.8	331
4	Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Modern Pathology, 2016, 29, 753-763.	5.5	230
5	High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. Radiology, 2020, 295, 254-272.	7.3	208
6	Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation. Journal of Immunology, 2002, 168, 4333-4343.	0.8	194
7	Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunology, Immunotherapy, 2008, 57, 1569-1577.	4.2	167
8	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunology, Immunotherapy, 2015, 64, 1271-1286.	4.2	161
9	Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. Journal of Controlled Release, 2012, 160, 88-95.	9.9	158
10	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
11	The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Frontiers in Immunology, 2017, 8, 631.	4.8	154
12	Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression. Clinical Cancer Research, 2017, 23, 3721-3733.	7.0	150
13	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clinical Cancer Research, 2021, 27, 3351-3359.	7.0	143
14	MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+precursors. Blood, 2002, 100, 701-703.	1.4	138
15	Sensing of latent EBV infection through exosomal transfer of 5â€²pppRNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E587-96.	7.1	136
16	CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. International Journal of Cancer, 2007, 121, 1749-1755.	5.1	134
17	Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. Journal of Immunology, 1999, 162, 6378-83.	0.8	128
18	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. Clinical Cancer Research, 2008, 14, 5884-5892.	7.0	127

#	ARTICLE	IF	CITATIONS
19	Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients. <i>Clinical Cancer Research</i> , 2007, 13, 2961-2969.	7.0	125
20	Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 4532-4542.	7.0	114
21	Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. <i>Radiology</i> , 2017, 282, 585-597.	7.3	111
22	CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis. <i>European Journal of Immunology</i> , 2008, 38, 3050-3059.	2.9	109
23	Transcriptional Profiling of Human Dendritic Cell Populations and Models - Unique Profiles of In Vitro Dendritic Cells and Implications on Functionality and Applicability. <i>PLoS ONE</i> , 2013, 8, e52875.	2.5	107
24	Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T lymphocytes and preserved MHC class I antigen expression. <i>International Journal of Cancer</i> , 2008, 123, 609-615.	5.1	104
25	Proteasome inhibitors as experimental therapeutics of autoimmune diseases. <i>Arthritis Research and Therapy</i> , 2015, 17, 17.	3.5	101
26	Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1241-1250.	4.2	98
27	High and Interrelated Rates of PD-L1+CD14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 48-58.	3.4	95
28	Human natural killer T cells acquire a memory-activated phenotype before birth. <i>Blood</i> , 2000, 95, 2440-2442.	1.4	94
29	Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 174-182.	2.5	92
30	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. , 2014, 2, 31.		92
31	Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. <i>Blood</i> , 2011, 118, 2502-2510.	1.4	90
32	Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. <i>Radiology</i> , 2020, 294, 212-220.	7.3	90
33	Clinical experience with $\beta$ -galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. <i>Clinical Immunology</i> , 2011, 140, 130-141.	3.2	87
34	ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. <i>Journal of Leukocyte Biology</i> , 2009, 86, 1075-1087.	3.3	83
35	Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. <i>International Journal of Cancer</i> , 2000, 88, 92-98.	5.1	79
36	T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 245-256.	4.2	79

#	ARTICLE	IF	CITATIONS
37	Bispecific antibody platforms for cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 153-165.	4.4	78
38	Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. <i>Oncolmmunology</i> , 2019, 8, 1652532.	4.6	75
39	Stereotactic ablative radiotherapy for the comprehensive treatment of $\leq 3$ Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. <i>BMC Cancer</i> , 2020, 20, 380.	2.6	75
40	Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1364-1373.	3.3	73
41	Technical Advance: Langerhans cells derived from a human cell line in a full-thickness skin equivalent undergo allergen-induced maturation and migration. <i>Journal of Leukocyte Biology</i> , 2011, 90, 1027-1033.	3.3	72
42	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0157830.	2.5	69
43	Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1017-1034.	3.3	67
44	Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188386.	7.4	67
45	Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors. <i>Journal of Immunology</i> , 2002, 169, 5322-5331.	0.8	66
46	MUTZ-3 derived Langerhans cells in human skin equivalents show differential migration and phenotypic plasticity after allergen or irritant exposure. <i>Toxicology and Applied Pharmacology</i> , 2015, 287, 35-42.	2.8	64
47	Local Administration of Granulocyte/Macrophage Colony-stimulating Factor Increases the Number and Activation State of Dendritic Cells in the Sentinel Lymph Node of Early-Stage Melanoma. <i>Cancer Research</i> , 2004, 64, 8456-8460.	0.9	63
48	Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. <i>Oncolmmunology</i> , 2012, 1, 649-658.	4.6	62
49	A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1505-1518.	4.2	62
50	A CD34+human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+Langerhans cell precursor. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1337-1344.	3.3	61
51	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V $\beta$ 9V $\gamma$ 2-T cells. <i>Oncolmmunology</i> , 2018, 7, e1375641.	4.6	61
52	A Postmigrational Switch among Skin-Derived Dendritic Cells to a Macrophage-Like Phenotype Is Predetermined by the Intracutaneous Cytokine Balance. <i>Journal of Immunology</i> , 2006, 176, 7232-7242.	0.8	59
53	Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage $\leq$ II Melanoma: Data from Two Randomized Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5679-5686.	7.0	57
54	Dendritic Cells Require Multidrug Resistance Protein 1 (ABCC1) Transporter Activity for Differentiation. <i>Journal of Immunology</i> , 2006, 176, 5191-5198.	0.8	56

#	ARTICLE	IF	CITATIONS
55	Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. , 2016, 4, 78.		56
56	Unlocking the therapeutic potential of primary tumor-draining lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1681-1688.	4.2	56
57	CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. <i>Vaccine</i> , 2003, 21, 2268-2272.	3.8	55
58	Applying ceramic nanoporous microneedle arrays as a transport interface in egg plants and an ex-vivo human skin model. <i>Microelectronic Engineering</i> , 2012, 98, 659-662.	2.4	55
59	In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1480-1490.	4.2	54
60	Selective tumor antigen vaccine delivery to human CD169 antigen-presenting cells using ganglioside-liposomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27528-27539.	7.1	54
61	Arming oncolytic viruses to leverage antitumor immunity. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 959-971.	3.1	53
62	PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. <i>Frontiers in Immunology</i> , 2020, 11, 596825.	4.8	53
63	Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2012, 30, 567-570.	1.6	52
64	Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8 <sup>+</sup> T cell cross-priming. <i>European Journal of Immunology</i> , 2014, 44, 2415-2424.	2.9	52
65	Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy. <i>Frontiers in Immunology</i> , 2021, 12, 643291.	4.8	52
66	Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 6308-6319.	0.9	51
67	Epidermis-to-dermis migration of immature Langerhans cells upon topical irritant exposure is dependent on CCL2 and CCL5. <i>European Journal of Immunology</i> , 2010, 40, 2026-2034.	2.9	50
68	Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation. <i>Cancer Immunology Research</i> , 2015, 3, 495-505.	3.4	50
69	Pancreatic Cancer and Immunotherapy: A Clinical Overview. <i>Cancers</i> , 2021, 13, 4138.	3.7	49
70	A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. <i>Blood</i> , 2008, 112, 2353-2359.	1.4	48
71	Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets. <i>Theranostics</i> , 2019, 9, 5797-5809.	10.0	48
72	Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. <i>Oncotarget</i> , 2015, 6, 32484-32493.	1.8	48

#	ARTICLE	IF	CITATIONS
73	Up-Regulation of Drug Resistance-Related Vaults During Dendritic Cell Development. <i>Journal of Immunology</i> , 2002, 168, 1572-1578.	0.8	47
74	Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. <i>Cancers</i> , 2019, 11, 1266.	3.7	47
75	A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. <i>Vaccine</i> , 2009, 27, 7116-7124.	3.8	44
76	Inducing Antitumor T Cell Immunity: Comparative Functional Analysis of Interstitial Versus Langerhans Dendritic Cells in a Human Cell Line Model. <i>Journal of Immunology</i> , 2008, 180, 4540-4549.	0.8	43
77	Comparison of a novel CXCL12/CCL5 dependent migration assay with CXCL8 secretion and CD86 expression for distinguishing sensitizers from non-sensitizers using MUTZ-3 Langerhans cells. <i>Toxicology in Vitro</i> , 2010, 24, 578-585.	2.4	43
78	Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. <i>International Journal of Cancer</i> , 2015, 136, 127-137.	5.1	43
79	In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 87.	4.8	43
80	TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. <i>Oncotarget</i> , 2016, 7, 67087-67100.	1.8	43
81	Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. , 2019, 7, 43.		42
82	Transcriptional profiling of human skin-resident Langerhans cells and CD1a+dermal dendritic cells: differential activation states suggest distinct functions. <i>Journal of Leukocyte Biology</i> , 2008, 84, 143-151.	3.3	41
83	Transcriptional profiling reveals functional dichotomy between human slan+non-classical monocytes and myeloid dendritic cells. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1055-1068.	3.3	40
84	Sampling Tumor-Draining Lymph Nodes for Phenotypic and Functional Analysis of Dendritic Cells and T Cells. <i>American Journal of Pathology</i> , 2002, 161, 19-26.	3.8	39
85	Immune-competent human skin disease models. <i>Drug Discovery Today</i> , 2016, 21, 1479-1488.	6.4	39
86	Improving CLL VÎ±9VÎ±2-Tâ€“cell fitness for cellular therapy by ex vivo activation and ibrutinib. <i>Blood</i> , 2018, 132, 2260-2272.	1.4	39
87	High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. <i>Cancer Biology and Therapy</i> , 2005, 4, 289-294.	3.4	37
88	The ABC of dendritic cell development and function. <i>Trends in Immunology</i> , 2009, 30, 421-429.	6.8	37
89	Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells. <i>Cellular and Molecular Immunology</i> , 2017, 14, 360-370.	10.5	37
90	Circulating VÎ±24+VÎ±11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. <i>Clinical Immunology</i> , 2005, 114, 183-189.	3.2	36

#	ARTICLE	IF	CITATIONS
91	Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 560-575.	7.4	36
92	Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 455-462.	4.2	35
93	In situ Delivery of Antigen to DC-SIGN + CD14 + Dermal Dendritic Cells Results in Enhanced CD8 + T-Cell Responses. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2228-2236.	0.7	35
94	Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSFâ€Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content. <i>Clinical Cancer Research</i> , 2006, 12, 2826-2833.	7.0	34
95	CCL5 and CCL20 mediate immigration of Langerhans cells into the epidermis of full thickness human skin equivalents. <i>European Journal of Cell Biology</i> , 2012, 91, 765-773.	3.6	34
96	Intradermal Delivery of TLR Agonists in a Human Explant Skin Model: Preferential Activation of Migratory Dendritic Cells by Polyribosinic-Polyribocytidylic Acid and Peptidoglycans. <i>Journal of Immunology</i> , 2013, 190, 3338-3345.	0.8	34
97	Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence. <i>Cancer Immunology Research</i> , 2017, 5, 969-977.	3.4	34
98	Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. <i>Journal of Leukocyte Biology</i> , 2002, 72, 321-9.	3.3	34
99	Leukemia-Specific T-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1BB Targeting. <i>Clinical Cancer Research</i> , 2007, 13, 307-315.	7.0	33
100	Gingiva Equivalents Secrete Negligible Amounts of Key Chemokines Involved in Langerhans Cell Migration Compared to Skin Equivalents. <i>Journal of Immunology Research</i> , 2015, 2015, 1-11.	2.2	33
101	CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. <i>Frontiers in Immunology</i> , 2021, 12, 697840.	4.8	33
102	IL-21 in cancer immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e24522.	4.6	32
103	Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. , 2019, 7, 133.		32
104	Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine. <i>Cancer Research</i> , 2011, 71, 5827-5837.	0.9	31
105	Functional characterization of a STAT3-dependent dendritic cell-derived CD14<sup>+</sup> cell population arising upon IL-10-driven maturation. <i>Oncolmmunology</i> , 2013, 2, e23837.	4.6	31
106	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. <i>Current Opinion in Oncology</i> , 2015, 27, 482-488.	2.4	31
107	Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1598.	4.8	31
108	IL-10 Conditioning of Human Skin Affects the Distribution of Migratory Dendritic Cell Subsets and Functional T Cell Differentiation. <i>PLoS ONE</i> , 2013, 8, e70237.	2.5	31

#	ARTICLE	IF	CITATIONS
109	Matched Skin and Sentinel Lymph Node Samples of Melanoma Patients Reveal Exclusive Migration of Mature Dendritic Cells. <i>American Journal of Pathology</i> , 2005, 167, 1301-1307.	3.8	30
110	Monophosphoryl lipid A plus IFN $\beta$ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1185-1195.	4.2	30
111	Mut $\alpha$ -3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors. <i>Journal of Leukocyte Biology</i> , 2009, 87, 637-643.	3.3	30
112	Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14+ Cells at the Cross-Roads of Immune Activation and Suppression. <i>Frontiers in Immunology</i> , 2013, 4, 403.	4.8	30
113	Highly specific and potently activating V $\beta$ 9V $\alpha$ 2-T cell specific nanobodies for diagnostic and therapeutic applications. <i>Clinical Immunology</i> , 2016, 169, 128-138.	3.2	29
114	Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1990.	4.8	29
115	Irritant-Induced Migration of Langerhans Cells Coincides with an IL-10-Dependent Switch to a Macrophage-Like Phenotype. <i>Journal of Investigative Dermatology</i> , 2011, 131, 418-425.	0.7	28
116	Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. <i>Scientific Reports</i> , 2017, 7, 43873.	3.3	28
117	High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 51-61.	4.2	28
118	CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. <i>Oncotarget</i> , 2018, 7, e1490856.	4.6	28
119	A Bispecific Single-Domain Antibody Boosts Autologous V $\beta$ 9V $\alpha$ 2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 1744-1755.	7.0	28
120	Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 405-415.	4.2	27
121	Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses. <i>Frontiers in Immunology</i> , 2020, 11, 990.	4.8	27
122	Selective Transduction of Dendritic Cells in Human Lymph Nodes and Superior Induction of High-avidity Melanoma-reactive Cytotoxic T Cells by a CD40-targeted Adenovirus. <i>Journal of Immunotherapy</i> , 2010, 33, 706-715.	2.4	26
123	Epstein-Barr Virus-Encoded BART1 Protein is a Decoy Receptor for Macrophage Colony Stimulating Factor and Interferes with Macrophage Differentiation and Activation. <i>Viral Immunology</i> , 2012, 25, 461-470.	1.3	26
124	The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 503-515.	4.2	26
125	Intradermal Delivery of Adenoviral Type-35 Vectors Leads to High Efficiency Transduction of Mature, CD8+ T Cell-Stimulating Skin-Emigrated Dendritic Cells. <i>Journal of Immunology</i> , 2006, 177, 2208-2215.	0.8	25
126	Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. <i>Immunotherapy</i> , 2011, 3, 77-96.	2.0	25



#	ARTICLE	IF	CITATIONS
127	Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. <i>Oncolmunology</i> , 2017, 6, e1265717.	4.6	25
128	Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1096.	4.1	25
129	Attenuation of invariant Natural Killer T-cell anergy induction through intradermal delivery of $\beta$ -galactosylceramide. <i>Clinical Immunology</i> , 2010, 136, 364-374.	3.2	24
130	mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells. <i>Journal of Immunology</i> , 2015, 195, 2038-2045.	0.8	23
131	â€ˆDURVITâ€™: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment. <i>BMC Cancer</i> , 2018, 18, 888.	2.6	23
132	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes $\text{V}\beta$ 9 $\text{V}\beta$ 2 T cellâ€™-Mediated Antitumor Responses in Human B-cell Malignancies. <i>Cancer Immunology Research</i> , 2021, 9, 50-61.	3.4	23
133	Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR. <i>Oncotarget</i> , 2016, 7, 5240-5257.	1.8	23
134	Tumor-educated Tregs drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche. <i>Cell Reports</i> , 2022, 38, 110447.	6.4	23
135	Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. <i>Immunotherapy</i> , 2010, 2, 69-83.	2.0	22
136	CD40â€™-targeted adenoviral cancer vaccines: the long and winding road to the clinic. <i>Journal of Gene Medicine</i> , 2012, 14, 416-427.	2.8	22
137	Vaccination approach to anti-angiogenic treatment of cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 155-171.	7.4	22
138	Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 4722.	3.7	22
139	Cancer vaccine strategies get bigger and better. <i>Nature Medicine</i> , 1999, 5, 1124-1125.	30.7	21
140	A Single-Component CD40-Targeted Adenovirus Vector Displays Highly Efficient Transduction and Activation of Dendritic Cells in a Human Skin Substrate System. <i>Molecular Pharmaceutics</i> , 2005, 2, 218-223.	4.6	21
141	CD14 <sup>+</sup> macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?. <i>Oncolmunology</i> , 2015, 4, e1009296.	4.6	21
142	Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells. <i>Clinical Immunology</i> , 2016, 168, 47-54.	3.2	21
143	Immunological effects of everolimus in patients with metastatic renal cell cancer. <i>International Journal of Immunopathology and Pharmacology</i> , 2017, 30, 341-352.	2.1	21
144	A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response. <i>Nature Cancer</i> , 2020, 1, 1054-1065.	13.2	21

#	ARTICLE	IF	CITATIONS
145	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. <i>ERJ Open Research</i> , 2017, 3, 00110-2016.	2.6	20
146	Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2319-2331.	4.2	20
147	Liposomal Nanovaccine Containing Î±-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. <i>Vaccines</i> , 2021, 9, 56.	4.4	20
148	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4045-4045.	1.6	20
149	CD1d-Restricted Antigen Presentation by VÎ³9VÎ³2-T Cells Requires Trogocytosis. <i>Cancer Immunology Research</i> , 2014, 2, 732-740.	3.4	19
150	Immunomodulation of the melanoma sentinel lymph node: A novel adjuvant therapeutic option. <i>Immunobiology</i> , 2006, 211, 651-661.	1.9	18
151	Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. <i>Vaccine</i> , 2011, 29, 2313-2321.	3.8	18
152	Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 181-191.	4.2	18
153	Phenotypic and Functional Properties of Human Steady State CD14+ and CD1a+ Antigen Presenting Cells and Epidermal Langerhans Cells. <i>PLoS ONE</i> , 2015, 10, e0143519.	2.5	18
154	Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination?. <i>Chinese Clinical Oncology</i> , 2019, 8, 61-61.	1.2	18
155	Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0â€“1 non-small cell lung cancer: the INCREASE trial. <i>BMC Cancer</i> , 2020, 20, 764.	2.6	18
156	Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. <i>Cancers</i> , 2021, 13, 711.	3.7	18
157	Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. <i>Cancers</i> , 2021, 13, 3902.	3.7	18
158	Local delivery of low-dose antiâ€“CTLA-4 to the melanoma lymphatic basin leads to systemic T<sub>reg</sub> reduction and effector T cell activation. <i>Science Immunology</i> , 2022, 7, .	11.9	18
159	Constitutively Active STAT5b Induces Cytokine-Independent Growth of the Acute Myeloid Leukemiaâ€“Derived MUTZ-3 Cell Line and Accelerates Its Differentiation Into Mature Dendritic Cells. <i>Journal of Immunotherapy</i> , 2006, 29, 188-200.	2.4	17
160	Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. <i>Experimental Hematology and Oncology</i> , 2013, 2, 2.	5.0	17
161	Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. <i>Oncolmmunology</i> , 2021, 10, 1954807.	4.6	17
162	A Multi-Organ-on-Chip Approach to Investigate How Oral Exposure to Metals Can Cause Systemic Toxicity Leading to Langerhans Cell Activation in Skin. <i>Frontiers in Toxicology</i> , 2021, 3, 824825.	3.1	17

#	ARTICLE	IF	CITATIONS
163	Adenovirus-Based Immunotherapy of Cancer: Promises to Keep. <i>Advances in Cancer Research</i> , 2012, 115, 147-220.	5.0	16
164	Activated iNKT cells promote V $\beta$ 39V $\alpha$ 2-T cell anti-tumor effector functions through the production of TNF- $\alpha$ . <i>Clinical Immunology</i> , 2012, 142, 194-200.	3.2	16
165	Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes. <i>Frontiers in Immunology</i> , 2018, 9, 1619.	4.8	16
166	Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes. <i>Haematologica</i> , 2022, 107, 655-667.	3.5	16
167	The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma. <i>Current Topics in Microbiology and Immunology</i> , 2011, 351, 181-220.	1.1	15
168	Priming of PRAME- and WT1-specific CD8 <sup>+</sup> T cells in healthy donors but not in AML patients in complete remission. <i>Oncolimmunology</i> , 2013, 2, e23971.	4.6	15
169	Comparative phenotypic and functional analysis of migratory dendritic cell subsets from human oral mucosa and skin. <i>PLoS ONE</i> , 2017, 12, e0180333.	2.5	15
170	Identification and Characterization of ErbB-3-Binding Protein-1 as a Target for Immunotherapy. <i>Journal of Immunology</i> , 2007, 179, 2005-2012.	0.8	14
171	Selective Transduction of Mature DC in Human Skin and Lymph Nodes by CD80/CD86-targeted Fiber-modified Adenovirus-5/3. <i>Journal of Immunotherapy</i> , 2009, 32, 895-906.	2.4	14
172	Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 37-47.	4.2	14
173	Generation and characterization of CD1d $\alpha$ -specific single $\alpha$ -domain antibodies with distinct functional features. <i>Immunology</i> , 2016, 149, 111-121.	4.4	14
174	MUTZ-3 Langerhans Cell maturation and CXCL12 independent migration in reconstructed human gingiva. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2016, 33, 423-434.	1.5	14
175	Autologous tumor cell vaccination combined with systemic CpG-B and IFN- $\alpha$ promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1025-1035.	4.2	13
176	Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8 <sup>+</sup> T Cells and Elevated $\beta$ -Catenin Activation Compared with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3791-3802.	7.0	13
177	Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. <i>Physiological Reports</i> , 2021, 9, e14919.	1.7	13
178	Adenovirus Armed With TNF $\alpha$ and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. <i>Frontiers in Immunology</i> , 2021, 12, 706517.	4.8	13
179	Unimpaired immune functions in the absence of Mrp4 (Abcc4). <i>Immunology Letters</i> , 2009, 124, 81-87.	2.5	12
180	Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. <i>Journal of Translational Medicine</i> , 2013, 11, 152.	4.4	12

#	ARTICLE	IF	CITATIONS
181	Differential capacity of human interleukin-4 and interferon- $\gamma$ monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1419-1427.	4.2	12
182	Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. <i>Current Oncology Reports</i> , 2021, 23, 68.	4.0	12
183	Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth. , 2021, 9, e003623.		12
184	Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. <i>Cancers</i> , 2021, 13, 5446.	3.7	12
185	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Oncolimmunology</i> , 2016, 5, e1105431.	4.6	11
186	Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 319-329.	4.2	11
187	HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial. , 2021, 9, e002547.		11
188	Preferential Langerhans cell differentiation from CD34 <sup>+</sup> precursors upon introduction of ABCG2 (BCRP). <i>Immunology and Cell Biology</i> , 2012, 90, 206-215.	2.3	10
189	Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway. , 2020, 8, e000761.		10
190	Prevention of $\text{V}\beta 9\text{V}\beta 2$ T Cell Activation by a $\text{V}\beta 9\text{V}\beta 2$ TCR Nanobody. <i>Journal of Immunology</i> , 2017, 198, 308-317.	0.8	9
191	Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells. <i>Current Opinion in Chemical Biology</i> , 2019, 53, 167-172.	6.1	9
192	T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A <sup>+</sup> CD141 <sup>+</sup> cDC1 and CD14 <sup>+</sup> antigen-presenting cell recruitment. , 2021, 9, e001962.		9
193	The role of transforming growth factor $\beta 2$ in upper gastrointestinal cancers: A systematic review. <i>Cancer Treatment Reviews</i> , 2021, 100, 102285.	7.7	9
194	Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1101.	2.4	9
195	The novel bispecific diabody $\beta$ CD40/ $\beta$ CD28 strengthens leukaemic dendritic cell-induced T cell reactivity. <i>British Journal of Haematology</i> , 2008, 142, 273-283.	2.5	8
196	Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34 <sup>+</sup> precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. <i>Immunotherapy</i> , 2011, 3, 1051-1061.	2.0	8
197	Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. <i>Immunotherapy</i> , 2013, 5, 859-868.	2.0	8
198	Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs. <i>Vaccines</i> , 2018, 6, 42.	4.4	8

#	ARTICLE	IF	CITATIONS
199	Constitutively active GSK3 $\beta$ as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression. <i>Oncolmmunology</i> , 2019, 8, e1631119.	4.6	8
200	Expression of Oncolytic Adenovirus-Encoded RNAi Molecules Is Most Effective in a pri-miRNA Precursor Format. <i>Molecular Therapy - Oncolytics</i> , 2020, 19, 332-343.	4.4	8
201	Feasibility of flowcytometric quantitation of immune effector cell subsets in the sentinel lymph node of the breast after cryopreservation. <i>Journal of Immunological Methods</i> , 2012, 375, 189-195.	1.4	7
202	Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells. <i>Clinical and Experimental Immunology</i> , 2020, 201, 145-160.	2.6	7
203	Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma. <i>Human Gene Therapy</i> , 2021, 32, 178-191.	2.7	7
204	High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 943-951.	4.2	6
205	Hematopoietic Cancer Cell Lines Can Support Replication of Sabin Poliovirus Type 1. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	6
206	A safety and immunogenicity study of immunization with hVEGF 26-104 /RFASE in cynomolgus monkeys. <i>Vaccine</i> , 2018, 36, 2025-2032.	3.8	6
207	Human natural killer T cells acquire a memory-activated phenotype before birth. <i>Blood</i> , 2000, 95, 2440-2442.	1.4	6
208	In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity. <i>Oncolmmunology</i> , 2014, 3, e946360.	4.6	5
209	In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma. <i>Oncolmmunology</i> , 2020, 9, 1708066.	4.6	5
210	Exploiting the CD1d-iNKT Cell Axis for Potentiation of DC-Based Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2014, 1139, 155-165.	0.9	5
211	Clinical and Immunological Results Of a Phase I/IIa Study Of Allogeneic Dendritic Cell (DC) Vaccination, An "off The shelf" Treatment To Prevent Or Delay Relapse In Elderly Patients With Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2651-2651.	1.4	5
212	Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1622-1632.	3.3	4
213	A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. <i>British Journal of Cancer</i> , 2016, 115, 940-948.	6.4	4
214	From Local to Systemic Treatment: Leveraging Antitumor Immunity Following Irreversible Electroporation. , 2018, , 249-270.		4
215	The effects of systemic treatment with aminobisphosphonates and statins on circulating V $\beta$ 2-T cells in patients with advanced cancer. <i>Immunobiology</i> , 2018, 223, 171-177.	1.9	4
216	A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26 $\mu$ 104/RFASE in Patients with Advanced Solid Malignancies. <i>Oncologist</i> , 2021, 26, e218-e229.	3.7	4

#	ARTICLE	IF	CITATIONS
217	Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade. <i>Cells</i> , 2021, 10, 3233.	4.1	4
218	Effects of Antigen-Expressing Immunostimulatory Liposomes on Chemotaxis and Maturation of Dendritic Cells In Vitro and in Human Skin Explants. <i>Pharmaceutical Research</i> , 2014, 31, 516-526.	3.5	3
219	Apoptotic vesicles as tumor vaccine. <i>Immunotherapy</i> , 2016, 8, 5-8.	2.0	3
220	Immune checkpoint inhibition: from molecules to clinical application. <i>Clinical and Experimental Immunology</i> , 2020, 200, 105-107.	2.6	3
221	Palmitoylated antigens for the induction of anti-tumor CD8+ T <sup>H</sup> 1 cells and enhanced tumor recognition. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 315-328.	4.4	3
222	Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to $\gamma$ -T Cell Mediated Killing, Provided CLL-Derived $\gamma$ -T Cell Dysfunction Can be Reversed. <i>Blood</i> , 2015, 126, 2914-2914.	1.4	3
223	Procedures for the expansion of CD14+precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy. <i>Immunotherapy</i> , 2013, 5, 1183-1190.	2.0	2
224	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. <i>Clinical Immunology</i> , 2015, 158, 92-99.	3.2	2
225	Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 787-798.	4.2	2
226	Immunotherapy of Cancer by Dendritic Cell-Targeted Gene Transfer. , 2005, , 143-172.		2
227	Expansion of AML Blasts Induces CD14 Expression and Facilitates Leukemic DC Development for Therapeutic Application In AML. <i>Blood</i> , 2010, 116, 2193-2193.	1.4	2
228	$\gamma$ -T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e955343.	4.6	1
229	A Human Cell Line Model for Interferon- $\gamma$ Driven Dendritic Cell Differentiation. <i>PLoS ONE</i> , 2015, 10, e0135219.	2.5	1
230	A novel combinatorial therapy using cytolytic NK cells and anti-EGFR moAb to improve the treatment of EGFR expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14017-e14017.	1.6	1
231	CD141 Expressing Monocytes Show an Inflammatory Profile and Are Associated with Low-Risk Features in Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4298-4298.	1.4	1
232	Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: clinical and biological concepts. <i>Clinical and Translational Oncology</i> , 2004, 6, 130-139.	2.4	0
233	Antigen Targeting to Dendritic Cells for Cancer Immunotherapy. , 2013, , 147-171.		0
234	Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials. , 2015, 3, .		0

#	ARTICLE	IF	CITATIONS
235	Response to Comment on "mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells". Journal of Immunology, 2015, 195, 5101-5102.	0.8	0
236	The Novel Bispecific Diabody $\hat{I}\pm$ CD40/ $\hat{I}\pm$ CD28 Strengthens Leukemic Dendritic Cell Induced T Cell Reactivity.. Blood, 2006, 108, 3710-3710.	1.4	0
237	Comparative Analysis of CD8+ t Cell Priming Efficiencies against a Panel of Leukemia-Associated HLA-A2 Restricted Epitopes Identifies PRAME as a Possible Vaccination Target in AML. Blood, 2008, 112, 5441-5441.	1.4	0
238	Absence of Granzyme B Positive Tumour-Infiltrating Lymphocytes in Primary Melanoma Excisional Biopsies is Strongly Associated with the Presence of Sentinel Lymph Node Metastasis. Analytical Cellular Pathology, 2009, 31, 407-413.	1.4	0
239	Maturation by Toll Like Receptor Ligand R848 Improves the Uptake of Apoptotic Leukemic Cells by Monocyte Derived Dendritic Cells.. Blood, 2009, 114, 2075-2075.	1.4	0
240	Functional PRAME Specific T Cells Can Be Cultured From CD8+ Cells From Healthy Donors but Not From Patients at First CR: Implications for Immunotherapeutic Strategies in AML.. Blood, 2009, 114, 4139-4139.	1.4	0
241	Apoptotic Blebs From Leukemic Cells as a Source of Tumor Associated Antigen for Monocyte-Derived Dendritic Cell Loading. Blood, 2010, 116, 3283-3283.	1.4	0
242	Allogeneic dendritic cell (DC) vaccination as an "off the shelf" treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study.. Journal of Clinical Oncology, 2013, 31, 3029-3029.	1.6	0
243	Dendritic Cell Subsets in Bone Marrow and Peripheral Blood of Patients with Myelodysplastic Syndromes Display Numeric and Functional Defects. Blood, 2015, 126, 4109-4109.	1.4	0
244	Umbilical cord blood stem cell derived NK cells as universal treatment for metastatic colorectal cancer using EGFR independent killing mechanisms.. Journal of Clinical Oncology, 2016, 34, e14525-e14525.	1.6	0
245	Allogeneic NK cells generated from cord blood as universal treatment for cervical cancer enabled by HLA independent killing mechanisms.. Journal of Clinical Oncology, 2016, 34, e14526-e14526.	1.6	0